Page 194 of 294: studies 1,931 to 1,940 of 2,939, newest first. Back to the psychedelic-assisted therapy overview
August 30, 2024
Psychedelic-assisted therapy trials for depression have shown robust, rapid symptom reduction lasting weeks to months after treatment in some studies. The largest trial to date found a dose-dependent increase in suicidal ideation and behavior, suggesting potential risks. Psychedelics show promise in addressing depression and anxiety related to terminal illnesses.
Canadian Medical Education Journal August 30, 2024 Daniel Shane, Matthew Cho, Sabrina Akhtar 1 citation
Psychedelics in medicine - A call for educational action. An article from journal Canadian Medical Education Journal / Revue canadienne de l'éducation médicale (Volume 15, Number 4, 2024, pp. 1-144), on Érudit.
Research Square August 23, 2024 Mathias E. Jensen, Dea Siggaard Stenbæk, Catharina Messell et al. 1 citation preprint
Abstract Background Psilocybin, a serotonin 2A receptor agonist with psychedelic properties, shows promise as a novel treatment for alcohol use disorder (AUD). While current studies involve two dosing sessions, the effects a single dose have not been investigated. Aims To investigate the pharmacokinetics, feasibility, safety, and efficacy of single-dose psilocybin therapy in AUD. Methods This...
Journal of Psychedelic Studies August 21, 2024 J. H. Lichtenstein, Nicholas Hoeh 5 citations
Abstract There is a developing dialogue between the psychoanalytic and psychedelic fields of psychotherapy. This paper contributes to this emerging collaboration by applying Winnicott's concept of transitional experience to psychedelic clinical work. By analyzing two Ketamine-Assisted Psychotherapy (KAP) cases, we explore in depth how transitional experience facilitates psychedelic...
Philosophical Psychology August 20, 2024 Emiliano Loria, Elisabetta Lalumera, Ambra D’imperio 1 citation
The resurgence of interest in psychedelic substances for psychiatric treatment has sparked both excitement and scepticism within the scientific community. This paper addresses the moralisation and hype surrounding psychedelic therapies. Through a systematic review of the literature and a detailed case study, we illustrate that the therapeutic effect of psychedelics is not solely pharmacological...
Mental Health Weekly August 19, 2024 Valerie A. Canady
In a closely watched decision involving the use of psychedelic treatment and therapy to treat post‐traumatic stress disorder (PTSD), the U.S. Food and Drug Administration (FDA) on Aug. 9 declined to approve the use of midomafetamine (MDMA)‐assisted therapy for the disorder. The federal agency issued a Complete Response Letter (CRL) for MDMA‐assisted therapy to its drug maker, Lykos Therapeutics.
DergiPark (Istanbul University) August 19, 2024 Doğancan Sönmez, Aslı Enzel Koç
Psilosibin, klasik bir serotonerjik psikedelik madde olup, depresyon, anksiyete, travma sonrası stres bozukluğu, obsesif kompulsif bozukluk, yeme bozuklukları ve bağımlılık gibi ruhsal bozuklukların tedavisinde umut vaat etmektedir. Bu derleme, mevcut literatürü analiz ederek, psilosibinin terapötik etkilerini, olası mekanizmalarını ve klinik kullanımına dair etik ve yasal konuları ele...
Science August 16, 2024 Kai Kupferschmidt 12 citations
Lykos's failure to win FDA approval for PTSD therapy may accelerate a strategic shift among its competitors.
Revista fisio&terapia August 15, 2024 Alberto Almeida, Carlos Paulo da Silva, Clara Guerzoni et al.
This integrative review explores the use of psychedelics in psychiatry, focusing on their historical context, recent resurgence, and clinical efficacy in treating psychiatric disorders such as depression, PTSD, and anxiety. Initially, psychedelic therapies showed promise in the 1950s and 1970s but were diminished due to restrictive policies and stigma. However, a resurgence in clinical interest...
Research Square August 15, 2024 Paweł Holas, Justyna Kamińska preprint
Abstract Objective Recent years have witnessed a resurgence in research exploring the therapeutic potential of classic psychedelics like psilocybin and LSD for treating mental disorders. However, there is a limited knowledge regarding the epidemiology of classic psychedelics consumption and the factors associated with their recreational use in Poland. Methods A representative sample of Polish...